Skip to main content

Table 3 Improvement in symptom control

From: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

 

O'Brien 2006

Von Pawel 1999

Von Pawel 2001

Eckardt 2007

Improvement in:

Oral topotecan vs BSC

IV topotecan vs

CAV

Oral vs IV

topotecan

Oral vs IV topotecan#

Shortness of breath

OR 2.18 (1.09 to 4.38)

27.9% vs 6.6% P = 0.002

13.8% vs 27.3% P = 0.20$

0.009 (-0.21 to 0.23) vs 0.08 (-0.29 to 0.14) difference 0.08 (-0.22 to 0.39)†

Cough

OR 1.35 (0.68 to 2.66)

24.6% vs 14.8% P = 0.16

16.1% vs 22.2% P = 0.53$

0.14 (-0.07 to 0.36) vs 0.27 (0.07 to 0.46) difference -0.13 (-0.41 to 0.16)†

Chest pain

OR 2.07 (1.00 to 4.28)

25.0% vs 17.1% P = 0.371

42.1% vs 31.8% P = 0.50$

-0.18 (-0.40 to 0.03) vs 0.06 (-0.11 to 0.23) difference -0.24 (-0.52 to 0.03)†

Coughing up blood

OR 1.95 (0.46 to 8.27)

26.7% vs 33.3% P = 0.706

33.3% vs 40.0% P = 0.84$

 

Loss of appetite

OR 1.02 (0.57 to 1.84)

32.1% vs 15.8% P = 0.042

18.5% vs 31.0% P = 0.28$

 

Interference with sleep

OR 2.16 (1.15 to 4.06)

33.3% vs 18.9% P = 0.085

32.0% vs 26.6% P = 0.85$

 

Hoarseness

OR 1.35 (0.63 to 2.87)

32.5% vs 13.2% P = 0.043

35.7% vs 37.5% P = 0.91$

 

Fatigue

OR 2.29 (1.25 to 4.19)

22.9% vs 9.2%

P = 0.032

21.2% vs 16.7% P = 0.63$

 

Interference with

daily activities

OR 1.70 (0.95 to 3.03)

26.9% vs 11.1% P = 0.023

25.8% vs 22.2% P = 0.73$

 

Nausea

   

-0.42 (-0.60 to -0.24) vs -0.40 (-0.60 to -0.21) difference -0.02 (-0.28 to 0.24)†

Pain

   

-0.08 (-0.28 to 0.12) vs -0.40 (-0.60 to -0.21) difference 0.09 (-0.22 to 0.40)†

  1. Effects in bold show advantage for topotecan; effects in italics show advantage for best supportive care or CAV (none were found); numbers between brackets are 95% confidence intervals; BSC best supportive care; OR = odds ratio; vs versus; $ = own calculation from 2 by 2 data; † = data supplied by GlaxoSmithKline; # a positive change indicates improvement